This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: Satellos Bioscience Inc.
Today announced that the first patient has been dosed in the open-label, long-term follow-up study (LT-001) of SAT-3247 in adult males with Duchenne muscular dystrophy (Duchenne, or DMD). SAT-3247 is a novel oral small molecule therapeutic candidate designed to repair and regenerate muscle that is lost in people living with Duchenne. Satellos Bioscience Inc. shares T.MSCL are trading down $0.01 at $0.78.
